CCDC138: A Potential Drug Target and Biomarker (G165055)

Target Name: CCDC138

NCBI ID: G165055

CCDC138

CCDC138: A Potential Drug Target and Biomarker

CDC138 is a protein that is expressed in various tissues of the body, including the brain, pancreas, and gastrointestinal tract. It is a member of the cryptodysmian complex (CDC), which is a family of transmembrane proteins that play a role in cell signaling and tissue structure. The discovery of CDC138 as a potential drug target and biomarker has significant implications for the development of new treatments for various diseases, including neurodegenerative disorders, diabetes, and cancer.

CDC138's Structure and Function

CDC138 is a 21-kDa protein that consists of a catalytic domain and a transmembrane region. The catalytic domain is responsible for catalyzing the breakdown of intracellular signaling pathways, which is essential for the regulation of cellular processes, including cell growth, differentiation, and apoptosis. The transmembrane region is responsible for maintaining the protein's physical structure and for providing it with its unique biology, including its ability to interact with other proteins and molecules.

CDC138's Role in Diabetes

CDC138 has been shown to be involved in the regulation of glucose metabolism, which is a critical aspect of diabetes management. Studies have shown that CDC138 plays a role in the uptake and storage of glucose in the pancreas, as well as its release from the pancreas to regulate blood glucose levels. In addition, CDC138 has been shown to be involved in the regulation of insulin sensitivity, which is a key factor in the development of type 2 diabetes.

CDC138's Potential as a Drug Target

The potential of CDC138 as a drug target is due to its unique biology and its involvement in various cellular processes that are associated with the development and progression of diseases. One of the main targets of CDC138 is the regulation of cell signaling pathways, which is critical for the regulation of cellular processes, including cell growth, differentiation, and apoptosis.

Another potential target of CDC138 is the regulation of inflammation, which is a key factor in the development and progression of many diseases, including neurodegenerative disorders and cancer. Studies have shown that CDC138 is involved in the regulation of inflammation in various tissues, including the brain and the gastrointestinal tract.

In addition, CDC138 may also be a potential target for cancer, as its expression has been shown to be involved in the regulation of cell cycle progression and apoptosis. The regulation of cell cycle progression is a key factor in the development and progression of cancer, and targeting this process may be an effective way to treat this disease.

Conclusion

CDC138 is a protein that has significant implications as a potential drug target and biomarker. Its unique biology and involvement in various cellular processes make it an attractive target for the development of new treatments for neurodegenerative disorders, diabetes, and cancer. Further research is needed to fully understand the role of CDC138 in these diseases and to develop effective treatments based on this protein.

Protein Name: Coiled-coil Domain Containing 138

The "CCDC138 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCDC138 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets